Cargando…

Intravitreal Vascular Endothelial Growth Factor Inhibitor Therapy in Denmark and 5-Year Projections

This cohort study examines the use of intravitreal injections of vascular endothelial growth factor inhibitor in Denmark from 2007 through 2022 and forecasts future demand for this therapy.

Detalles Bibliográficos
Autores principales:	Thinggaard, Benjamin Sommer, Pedersen, Frederik, Grauslund, Jakob, Stokholm, Lonny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517372/ https://www.ncbi.nlm.nih.gov/pubmed/37738053 http://dx.doi.org/10.1001/jamanetworkopen.2023.35148

Ejemplares similares

Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study
por: Thinggaard, Benjamin Sommer, et al.
Publicado: (2023)

Retinal artery occlusion does not act as an independent marker of upcoming dementia: results from a Danish 20-year cohort study
por: Clausen, Anna Rebien, et al.
Publicado: (2023)

Diabetic retinopathy is a predictor of chronic respiratory failure: A nationwide register-based cohort study
por: Thinggaard, Benjamin Sommer, et al.
Publicado: (2023)

Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach
por: Petri, Anne-Sofie, et al.
Publicado: (2020)

Incidence and Determinants of Ventilation Tubes in Denmark
por: Pedersen, Tine Marie, et al.
Publicado: (2016)

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy
por: Kianersi, Farzan, et al.
Publicado: (2021)

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
por: Campbell, Robert J, et al.
Publicado: (2012)

Pituitary Apoplexy After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A Novel Complication
por: Kasl, Rebecca A., et al.
Publicado: (2015)

Nephrotic Syndrome with Focal Segmental Glomerulosclerosis Induced by Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitor
por: Kakeshita, Kota, et al.
Publicado: (2020)

Intravitreal Vascular Endothelial Growth Factor Inhibitor Use and Renal Function Decline in Patients with Diabetic Retinopathy
por: Ou, Shih-Hsiang, et al.
Publicado: (2022)

Association between Obstetric Complications and Intravitreal Anti-Vascular Endothelial Growth Factor Agents or Intravitreal Corticosteroids
por: Ben Ghezala, Inès, et al.
Publicado: (2022)

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
por: Hang, Abraham, et al.
Publicado: (2023)

Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension
por: Hanna, Ramy M, et al.
Publicado: (2018)

Cardiovascular morbidity and all-cause mortality in patients with retinal vein occlusion: a Danish nationwide cohort study
por: Frederiksen, Katrine Hartmund, et al.
Publicado: (2023)

Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease
por: Kameda, Yusuke, et al.
Publicado: (2018)

Healthcare expenditure of intravitreal anti‐vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema
por: Hertzberg, Silvia NW, et al.
Publicado: (2022)

Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity
por: Mirghorbani, Masoud, et al.
Publicado: (2022)

Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA
por: Bakri, Sophie J., et al.
Publicado: (2023)

Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use
por: Hanna, Ramy M., et al.
Publicado: (2020)

Bariatric surgery in individuals with type 2 diabetes is not associated with short or long-term risk of diabetic retinopathy progression: results from a nationwide cohort study
por: Thykjær, Anne S., et al.
Publicado: (2023)

Presumed Pyogenic Granuloma Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy
por: Jung, Jesse J, et al.
Publicado: (2011)

Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab
por: Wang, Donghyun, et al.
Publicado: (2014)

Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit
por: Fiebai, Bassey, et al.
Publicado: (2017)

Results of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Inflammatory Choroidal Neovascularization
por: Zina, Sourour, et al.
Publicado: (2021)

Staphylococcus lugdunensis Endophthalmitis Following Intravitreal Anti-vascular Endothelial Growth Factor Injections
por: Ahmed, Umar, et al.
Publicado: (2022)

Profile of Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Bhutan
por: Rai, Bhim Bahadur, et al.
Publicado: (2023)

Effect of repeated intravitreal anti-vascular endothelial growth factor drugs on corneal nerves
por: Qi, Yuanyuan, et al.
Publicado: (2023)

Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results
por: Park, Sang-Uk, et al.
Publicado: (2014)

Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline
por: Nikkhah, Homayoun, et al.
Publicado: (2018)

Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020)

Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
por: Chung, Eun Jee, et al.
Publicado: (2011)

Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of coats' disease in children
por: Kaul, Shalini, et al.
Publicado: (2010)

Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
por: Fernando Arevalo, J.
Publicado: (2013)

Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia
por: Al-Rashaed, Saba, et al.
Publicado: (2016)

Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
por: Ruão, Miguel, et al.
Publicado: (2017)

Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents
por: Labardini, Cecilia P., et al.
Publicado: (2018)

Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection
por: Kaya, Mahmut, et al.
Publicado: (2021)

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
por: Yoon, Jihyun, et al.
Publicado: (2021)

Intravitreal anti-vascular endothelial growth factor injections to treat post-trabeculectomy Swan syndrome
por: Feu-Basilio, Silvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sl5nm52bbpoam7brtlt864odvq